The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026

  • Lowest Price Guaranteed From USD 2,349

  • Published
    August 2016

  • Pages
    359

  • View Count
    1637

Example Insights

  1. With a current total / combined share of more than 70% in the overall non-insulin market, GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors represent the three most prominent anti-diabetic drug classes. In terms of  size, currently, the market of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors is worth over USD 4 billion, USD 10 billion and USD 2 billion respectively. Overall, the market is highly fragmented and well distributed across different regions.
  2. Combined, the three drug classes have over 20 approved drugs (accounting around 40 different formulations / fixed-dose combinations) for the treatment of type II diabetes. In addition, the clinical / preclinical pipeline is rich and has over 70 molecules in different stages of development. Of the three classes, DPP4 inhibitors currently has the maximum number of marketed drugs (over 10, excluding fixed-dose combinations). On the other hand, GLP-1 agonists represent the most active class of drugs with over 40 molecules under development. SGLT2 inhibitors are also emerging at a rapid pace and already have six marketed drugs across different regions. Semaglutide (Novo Nordisk), ITCA 650 (Intarcia Therapeutics), sotagliflozin (Sanofi / Lexicon Pharmaceuticals), ertugliflozin (Merck / Pfizer), retagliptin (Jiangsu Hengrui Medicine) and gosogliptin (SatRx / Pfizer) are examples of late stage drugs that are likely to receive approval in the near future.
  3. Overall we came across over 80 pharmaceutical companies actively engaged in the discovery, development and commercialization of non-insulin therapies. Established pharmaceutical players have captured a major share of the non-insulin anti-diabetic drugs market. In fact, AstraZeneca, BMS, Eli Lilly and Sanofi are developing non-insulin therapies across all the three drug classes. Several other companies such as Daiichi Sankyo, Janssen, Merck, Mitsubishi Tanabe Pharma, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda and Zealand Pharma have invested heavily in the development of multiple molecules belonging to these drug classes. A number of start-ups / small companies such as (in alphabetical order) Alteogen, Amunix, ArisGen, C4XD, Diartis Pharmaceuticals, Oramed Pharmaceutical, PegBio, Poxel, Rani Therapeutics, Receptos, SatRx, Sirona Biochem and Spitfire Pharma have entered this space and are also competing to gain a significant share in the overall non-insulin therapies market.
  4. In addition to increased competition of such therapies in the major geographies such as the US and EU, some stakeholders have focused on tapping a localized opportunity. Drugs such as teneligliptin (Mitsubishi Tanabe Pharma), trelagliptin (Takeda), ipragliflozin (Astellas Pharma/ Kotobuki Pharmaceutical) and luseogliflozin (Taisho Pharmaceutical) have been approved only in Japan. Similarly, retagliptin (Jiangsu Hengrui Medicine) and Uni-E4 (Uni-Bio Science Group) are in Phase III clinical development in China only.
  5. With a vision to increase patient compliance, several pharmaceutical companies have introduced fixed-dose formulations of different drugs. Prominent examples include Eucreas® / Galvumet® / Galvus Met® / Icandra® / Zomarist® (vildagliptin + metformin) (Novartis), INVOKAMET® / VOKANAMET® (canagliflozin + metformin) (Janssen Pharmaceutical Companies / Mitsubishi Tanabe Pharma / Daiichi Sankyo), JANUMET® / Velmetia® (sitagliptin + metformin) (Merck), Xigdua® (dapagliflozin + metformin) (Astra Zeneca / BMS) and Xultophy® / IDegLira (liraglutide + insulin degludec) (Novo Nordisk).
  6. Technological advancements are amongst the key future growth drivers. Drug developers are investigating new routes of administration using several innovative technology platforms, such as Axcess™ (Diabetology), Eligen® (Emisphere Technologies), PharmFilm® Technology (MonoSol Rx) and the Protein Oral Delivery (POD™) technology (Oramed Pharmaceuticals), to facilitate the oral administration of GLP-1 agonists. Other innovative technologies such as the Intravail® drug delivery platform are attempting to facilitate nasal administration.Companies such as ScinoPharm and Panacea Biotech are developing oral capsule formulations of DPP4 inhibitors. Their molecules, DBPR108 and PBL 1427, respectively, are still in the early stages of clinical development.SGLT2 inhibitors, primarily used to treat type II diabetes, are also being developed for the treatment of type I diabetes. Examples include sotagliflozin (Theracos) and remogliflozin (BHV Pharma).
  7. Dual agonist drugs are also being developed to provide more effective treatment options. Examples of molecules that target both the GLP-1 receptor and glucagon receptor include MK-8521 (Merck), TTP401 / LY2944876 (Transition Therapeutics / Eli Lilly), MEDI0382 (AstraZeneca), SAR425899 (Sanofi) and MOD-6030 / MOD-6031 (OPKO Biologics). On the other hand, NN9709 (Novo Nordisk) and SAR438335 (Sanofi) are being developed to act on both GLP-1 and GIP receptors.
  8. Several research institutes, companies and organization have made significant contribution to the discovery and overall development of these therapies. During the study, we identified over 400 key opinion leaders who have played critical role in the development of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors. In addition, we identified over 50 articles, published during the 12 months beginning January 2015, which focused on these three drug classes. The design of these studies primarily focussed on evaluating the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of the drugs. 
  9. Extensive efforts are being made by pharmaceutical companies to explore new and innovative therapeutic strategies and agents that are safer and more effective than the already available options. Many novel non-insulin therapies are under clinical development. Examples of these new anti-diabetic drug classes include glucokinase activators, GPR119 agonists, GCGR antagonists, 11-beta hydroxysteroid dehydrogenase type 1 inhibitors, glycogen phosphorylase inhibitors and PTP-1B antagonists.
  10. It is important to highlight that nearing patent expiries of currently available drugs and the potential health hazards associated with the use of some of these inhibitors are going to negatively impact the market growth. However, our overall outlook is highly promising. We believe that SGLT2 inhibitors are likely to grow at an annualized growth rate of ~17%, followed by GLP-1 agonists (expected growth rate of ~13.4%). 

Overview

Diabetes, considered to be the most common metabolic disorder in humans, is ranked among the top ten fatal diseases in the US. The increasing incidence, growing prevalence and the progressive nature of the disease has spurred several pharmaceutical companies to develop novel approaches / therapies to provide better treatment options for diabetic patients worldwide. While insulin supplements and insulin based therapies represent a major portion of the anti-diabetic drugs market, non-insulin therapies are first line therapies designed especially for patients suffering from type II diabetes. 

Sulfonylureas, biguanides, glinides, TZDs and alpha- glucosidase inhibitors were the first classes of non-insulin therapies to hit the market. Subsequently, incretin based therapies, such as GLP-1 agonists and DPP4 inhibitors, emerged as the standard of care for the treatment of type II diabetes. More recently, SGLT2 inhibitors have also been identified as an effective treatment solution for the same patient population. These three classes have captured a significant portion of the overall anti-diabetes market in a relatively short time span.

GLP-1 agonists and DPP4 inhibitors were introduced in the market over a decade ago while the first SGLT2 inhibitor was approved only in 2012. A number of drugs have emerged as blockbusters; examples include VICTOZA® (GLP-1 agonist), JANUVIA® / JANUMET® (DPP4 inhibitor) and INVOKANA® / INVOKAMET® (SGLT2 inhibitor).

Several companies, including both big pharmaceutical players and small to mid-sized companies, are active in this area. Companies engaged in developing anti-diabetic drug classes have actively entered into collaborations with other stakeholders to either acquire / develop / commercialize candidate therapies or for technology licensing. For instance, Tobira acquired the exclusive rights to develop and commercialize evogliptin from Dong-A ST in April 2016; Eli Lilly and Sumitomo Dainippon Pharma entered into a sales collaboration agreement for Trulicity® in July 2015; Novo Nordisk in-licensed Zosano’s technology to develop a transdermal patch formulation of Novo’s GLP-1 analogs, including semaglutide in February 2014; Takeda and Sanofi signed a co-promotion agreement for alogliptin in China in April 2013.

Recently issued FDA warnings specifically for DPP4 and SGLT2 inhibitors are likely to impact their adoption. However, new advances in drug development and the introduction of novel technologies are expected to help stakeholders operate within a proper framework and work towards eliminating the current gaps.

 

Scope of the Report

The “Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016-2026” report provides a comprehensive analysis of the current market landscape of these therapies and an informed opinion on how the market is likely to evolve over the next decade. The anti-diabetic drugs market broadly comprises of insulin and non-insulin therapies. Non-insulin therapies are further classified under various categories based on their respective mechanisms of action. Of the different types of non-insulin therapies, GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors have been the most popular in the last few years. As mentioned earlier, these therapeutic classes have captured the attention of a number of pharmaceutical companies and drug developers worldwide. Several companies, including pharmaceutical giants, mid-sized players and start-ups, have come up with innovative technologies and novel formulations of these drug classes. Such advances have generated and sustained significant momentum in this segment of the industry. Specifically, GLP-1 agonists, which have been researched for several years, have a rich pipeline of clinical and preclinical molecules. DPP4 inhibitors currently have a relatively larger market share; however, they are now giving way to other relatively newer and emerging classes such as SGLT2 inhibitors.

During the course of our study, we identified over 80 molecules belonging to these three drugs classes. More than 70% of the candidates are currently under clinical / preclinical development; the efforts are actively being led by several companies. Focused primarily on these three classes of drugs, this report features:

  • An overview of the market landscape highlighting important details on each molecule such as key players, current phase of product development, route of administration and dosage regime.
  • Detailed profiles of drugs that have been recently approved / marketed or are in the late stages of development. 
  • A list of key opinion leaders (KOLs) who were involved in the discovery and development of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors.
  • An analysis of recently published clinical trial data depicting the prevalent trends and technical developments that have taken place in the industry.
  • A discussion on the potential side effects and warnings issued by regulatory authorities suggesting areas of improvement / guidance for future drug development. 
  • A list of upcoming non-insulin novel therapies that are currently in early stages of development and likely to become a part of the anti-diabetic drugs market in the near future.

The report also provides an estimate of the likely future size of the non-insulin therapies for diabetes. Our forecast model was built based on an understanding of the existing market trends and likely future opportunities for GLP-1 agonists, DPP4 inhibitors, SGLT2 inhibitors and other non-insulin anti-diabetic drug classes. We have provided informed estimates of the expected future sales of marketed and late stage product candidates under each category, highlighting their share in the overall market over the next ten years.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzedfrom publicly available data. Unless otherwise specified, all financial figures are presented in USD.

Contents

Chapter 2  is an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors during the coming decade.

Chapter 3  provides a general introduction to diabetes and discusses associated symptoms, available diagnostic methods and tests, and other complications associated with the condition. It also includes a detailed classification of the various therapeutic interventions available for the treatment of diabetes. These include both insulin based and non-insulin therapies. The chapter also provides brief descriptions of their respective mechanisms of action.

Chapter 4  provides a comprehensive overview of the market landscape of GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors. It includes information on over 100 different molecules that fall under these classes of drugs. Some of these are already approved and are available in different regions across the globe. The rest are currently in various stages of preclinical / clinical development. The chapter presents analysis of the molecules based on their current phase of development, the various routes of administration being considered for their systemic delivery, dosage frequency, type of molecule and key players involved in developing these molecules.

Chapter 5  contains detailed profiles of recently approved and late stage GLP-1 agonists. Each profile covers information on several aspects of these drugs such as their history of development, clinical trial results, dosage form and regime, recent sales of the product (for marketed drugs), the current status of development, and the collaborations and partnerships that have been inked related to that particular drug / drug candidate.

Chapter 6  contains detailed profiles of recently approved and late stage DPP4 inhibitors. Each profile covers information on several aspects of these drugs such as their history of development, clinical trial results, dosage form and regime, recent sales of the product (for marketed drugs), the current status of development, and the collaborations and partnerships that have been inked related to that particular drug / drug candidate.

Chapter 7  contains detailed profiles of recently approved and late stage SGLT2 inhibitors. Each profile covers information on several aspects of these drugs such as their history of development, clinical trial results, dosage form and regime, recent sales of the product (for marketed drugs), the current status of development, and the collaborations and partnerships that have been inked related to that particular drug / drug candidate.

Chapter 8  focusses on the various side effects reported by patients treated using these drugs. It includes detailed discussions on the potential complications that may arise upon using these drugs, and the warnings issued by the FDA and other regulatory bodies regarding the associated risks. In addition, the chapter lists the various GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors that have been terminated during development due to various reasons.

Chapter 9  provides a brief introduction to other novel interventions that are currently being investigated as potential treatment options for diabetes. The chapter also includes an analysis of these novel therapeutic options based on the type of molecule being investigated and phase of development.

Chapter 10  provides a detailed analysis on the likely future size of the non-insulin therapies market over the next decade. It presents comprehensive forecast scenarios for each individual drug class mentioned in the report, namely GLP-1 agonists, DPP4 inhibitors, SGLT2 inhibitors and other non-insulin anti-diabetic drugs.

Chapter 11  presents an analysis of the Key Opinion Leaders (KOLs) in this domain. It contains schematic representations of world maps highlighting the geographical locations of these eminent scientists / researchers. The chapter presents a detailed 2X2 analysis to assess the relative experience of certain KOLs based on the number of clinical studies they participated in and the highest phase of development they investigated.

Chapter 12  provides a detailed analysis of recently published clinical data on GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors. It identifies various aspects of the ongoing research and presents analysis highlighting the active drugs, study focus areas and clinical endpoints (safety / efficacy / tolerability / pharmacodynamics / pharmacokinetics) across the published data.

Chapter 13  is a collection of interview transcripts of the discussions we held with key stakeholders in the industry.

Chapter 14  summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 15  is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 16  is an appendix,which contains the list of companies and organizations that have been mentioned in the report.

Table of Contents

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Introduction
3.1. Chapter Overview
3.2. Diabetes: Introduction
3.2.1. Diabetes: Classification
3.2.2. Diabetes: Symptoms
3.2.3. Diabetes: Diagnosis
3.2.4. Diabetes: Associated Health Risks / Complications
3.2.5. Diabetes: Therapies
3.2.5.1. Insulin Therapies
3.2.5.2. Non-Insulin Therapies
3.2.5.2.1. Alpha-glucosidase Inhibitors
3.2.5.2.2. Amylin Agonists
3.2.5.2.3. Biguanides
3.2.5.2.4. Dipeptidyl peptidase-4 (DPP4) inhibitors
3.2.5.2.5. Glinides / Meglitinides
3.2.5.2.6. GLP-1 Analogs / GLP-1 Agonists
3.2.5.2.7. Sodium-glucose cotransporter 2 (SGLT2) Inhibitors
3.2.5.2.8. Sulfonylureas
3.2.5.2.9. Thiazolidinediones (or ‘glitazones’or TZDs)
 
4. Market Overview
4.1. Chapter Overview
4.2. Non-Insulin Anti-Diabetic Therapies: History of Development / Evolution Timeline
4.3. GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors: Overall Market Overview
4.4. GLP-1 Agonists: Current Market Landscape
4.4.1. GLP-1 Agonists: Approved Drugs
4.4.2. GLP-1 Agonists: Pipeline Drugs
4.4.3. GLP-1 Agonists: Key Players
4.4.4. GLP-1 Agonists: Distribution by Route of Administration
4.4.5. GLP-1 Agonists: Distribution by Dosage Frequency
4.4.6. GLP-1 Agonists: Distribution by Type of Molecule
 
4.5. DPP4 Inhibitors: Current Market Landscape
4.5.1. DPP4 Inhibitors: Approved Drugs
4.5.2. DPP4 Inhibitors: Pipeline Drugs
4.5.3. DPP4 Inhibitors: Key Players
4.5.4. DPP4 Inhibitors: Distribution by Type of Therapy
4.5.5. DPP4 Inhibitors: Distribution by Dosage Frequency
 
4.6. SGLT2 Inhibitors: Current Market Landscape
4.6.1. SGLT2 Inhibitors: Approved Drugs
4.6.2. SGLT2 Inhibitors: Pipeline Drugs
4.6.3. SGLT2 Inhibitors: Key Players
4.6.4. SGLT2 Inhibitors: Distribution by Type of Therapy
4.6.5. SGLT2 Inhibitors: Distribution by Dosage Frequency
4.7. GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors: Key Players
 
5. GLP-1 Agonists
5.1. Chapter Overview
5.2. Albiglutide (GSK)
5.2.1. Product Overview
5.2.2. History of Development
5.2.3. Dosage Form, Regimen and Price
5.2.4. Historical Sales
5.2.5. Current Status of Development
5.2.6. Key Clinical Trial Results
5.2.6.1. Harmony 1 Study (Abstract Number: 2013-LB-5644)
5.2.6.2. Harmony 2 Study (Abstract Number: 2013-LB-5749)
5.2.6.3. Harmony 3 Study (Abstract Number: 2013-LB-5750)
5.2.6.4. Harmony 4 Study (Abstract number: 2013-LB-5751)
5.2.6.5. Harmony 5 Study (Abstract Number: 2013-LB-5752)
5.2.6.6. Harmony 6 Study
5.2.6.7. Harmony 7 Study
5.2.6.8. Harmony 8 Study
5.2.7. Recent Collaborations
 
5.3. Dulaglutide (Eli Lilly / Sumitomo Dainippon Pharma)
5.3.1. Product Overview
5.3.2. History of Development
5.3.3. Dosage Form, Regimen and Price
5.3.4. Historical Sales
5.3.5. Current Status of Development
5.3.6. Key Clinical Trial Results
5.3.6.1. AWARD-1
5.3.6.2. AWARD-2
5.3.6.3. AWARD-3
5.3.6.4. AWARD-4
5.3.6.5. AWARD-5
5.3.6.6. AWARD-6
5.3.6.7. AWARD-8
5.3.6.8. AWARD-9
5.3.6.9. Trulicity® versus Lantus®
5.3.6.10. Trulicity® versus Victoza®
5.3.7. Recent Collaborations
 
5.4. ITCA 650 (Intarcia Therapeutics / Servier)
5.4.1. Product Overview
5.4.2. History of Development
5.4.3. Intarcia’s Technology Platform
5.4.4. Current Status of Development
5.4.5. Key Clinical Trial Results
5.4.5.1. FREEDOM 1 HBL: Interim Results
5.4.5.2. FREEDOM-1 and FREEDOM-1 HBL: Top-Line Results
5.4.5.3. FREEDOM-2 Comparative Trial: Top-Line Results
5.4.5.4. FREEDOM-CVO: Top-Line Results
5.4.6. Funding
5.4.7. Recent Collaborations
 
5.5. Polyethylene Glycol Loxenatide / PEX 168 (Jiangsu Hansoh Pharmaceutical)
5.5.1. Product Overview
5.5.2. Current Status of Development
5.5.3. Key Clinical Trial Results
 
5.6. Semaglutide / NN9535 / NN9924 / OG217SC (Novo Nordisk/Emisphere)
5.6.1. Product Overview
5.6.2. History of Development
5.6.3. NN9924 and the Eligen® Technology
5.6.4. Manufacturing
5.6.5. Dosage Form and Regimen
5.6.6. Current Status of Development
5.6.6.1. PIONEER Clinical Program
5.6.6.2. SUSTAIN Clinical Program
5.6.7. Key Clinical Trial Results
5.6.7.1. NN9535: Phase III Results
5.6.7.2. NN9924/OG217SC: Phase II Results
5.6.8. Recent Collaborations
 
5.7. Uni-E4 (Uni-Bio Science Group)
5.7.1. Product Overview
5.7.2. Key Clinical Trial Results
 
6. DPP4 Inhibitors / CD26 Antigen Antagonists
6.1. Chapter Overview
6.2. Alogliptin (Takeda / Furiex Pharmaceuticals (Acquired by Forest Laboratories))
6.2.1. Product Overview
6.2.2. History of Development
6.2.3. Dosage Form, Regimen and Price
6.2.4. Historical Sales
6.2.5. Current Status of Development
6.2.6. Key Clinical Trial Results
6.2.6.1. EXAMINE Program
6.2.6.2. ENDURE Trial
6.2.7. Recent Collaborations
 
6.3. Trelagliptin (Takeda / 3SBio)
6.3.1. Product Overview
6.3.2. History of Development
6.3.3. Dosage Form, Regimen and Price
6.3.4. Current Status of Development
6.3.5. Key Clinical Trial Results
6.3.6. Recent Collaborations
 
6.4. Omarigliptin (Merck)
6.4.1. Product Overview
6.4.2. History of Development
6.4.3. Current Status of Development
6.4.4. Key Clinical Trial Results
 
6.5. Evogliptin (Dong-A Pharmaceutical / Luye Pharma Group / Eurofarma / Geropharm / Alkem Labs)
6.5.1. Product Overview
6.5.2. Dosage Forms, Regimen and Price
6.5.3. Current Status of Development
6.5.4. Key Clinical Trial Results
6.5.5. Recent Collaborations
 
6.6. Gosogliptin (SatRx / Pfizer)
6.6.1. Product Overview
6.6.2. Current Status of Development
6.6.3. Recent Collaborations
 
6.7. Retagliptin (Jiangsu Hengrui Medicine)
6.7.1. Product Overview
6.7.2. Current Status of Development
 
7. SGLT2 Inhibitors
7.1. Chapter Overview
7.2. Canagliflozin (Mitsubishi Tanabe Pharma / Janssen / Daiichi Sankyo)
7.2.1. Product Overview
7.2.2. History of Development
7.2.3. Dosage Form, Regimen and Price
7.2.4. Historical Sales
7.2.5. Current Status of Development
7.2.6. Key Clinical Trial Results
7.2.6.1. Long Term Effects in Older Type II Diabetic Patients
7.2.6.2. Real-World Analysis
7.2.6.3. Comparison between INVOKANA® and Other DPP4 Inhibitors
7.2.7. Recent Collaborations
 
7.3. Luseogliflozin (Taisho Pharmaceutical / Taisho Toyama Pharmaceutical / Novartis)
7.3.1. Product Overview
7.3.2. History of Development
7.3.3. Dosage Form, Regimen and Price
7.3.4. Current Status of Development
7.3.5. Key Clinical Trial Results
7.3.5.1. As a Monotherapy
7.3.5.1.1. Study 1: Placebo Controlled (24 weeks)
7.3.5.1.2. Study 2: Long-Term Treatment (52 weeks)
7.3.5.2. As Combination Therapy
7.3.5.2.1. Study 1: Combination with Glimepiride
7.3.5.2.2. Study 2: Combination with Metformin, DPP4 inhibitor, Pioglitazone, Glinides or alpha-glucosidase inhibitor
7.3.6. Historical Sales
7.3.7. Recent Collaborations
 
7.4. Tofogliflozin (Chugai Pharmaceutical / Sanofi / Kowa)
7.4.1. Product Overview
7.4.2. History of Development
7.4.3. Current Status of Development
7.4.4. Key Clinical Trial Results
7.4.4.1. As a Monotherapy
7.4.5. Recent Collaborations
 
7.5. Empagliflozin (Boehringer Ingelheim / Eli Lilly)
7.5.1. Product Overview
7.5.2. History of Development
7.5.3. Dosage Form, Regimen and Price
7.5.4. Manufacturing
7.5.5. Current Status of Development
7.5.6. Key Clinical Trial Results
7.5.6.1. As a Monotherapy: Retrospective Data
7.5.6.2. As a Fixed-Dose Combination Therapy
7.5.6.2.1. Combination with Metformin
7.5.6.2.2. Combination with Linagliptin
7.5.6.3. CV Outcome Results (EMPA-REG OUTCOME®)
7.5.7. Recent Collaborations
 
7.6. Ipragliflozin (Astellas Pharma / Kotobuki Pharmaceutical / MSD K.K.)
7.6.1. Product Overview
7.6.2. History of Development
7.6.3. Dosage Form, Regimen and Price
7.6.4. Current Status of Development
7.6.5. Key Clinical Trial Results
7.6.5.1. As a Monotherapy
7.6.5.2. As a Combination Therapy
7.6.6. Recent Collaborations
 
7.7. Bexagliflozin (Theracos)
7.7.1. Product Overview
7.7.2. Current Status of Development
7.7.3. Key Clinical Trial Results
 
7.8. Ertugliflozin (PF-04971729, MK-8835) (Pfizer /Merck)
7.8.1. Product Overview
7.8.2. Current Status of Development
7.8.3. Key Clinical Trial Results
7.8.3.1. As a Monotherapy: VERTIS Mono
7.8.3.2. As a Combination Therapy with JANUVIA®: VERTIS Factorial
7.8.4. Recent Collaborations
 
7.9. Sotagliflozin (Lexicon/Sanofi)
7.9.1. Product Overview
7.9.2. History of Development
7.9.3. Current Status of Development
7.9.4. Key Clinical Trial Results
7.9.4.1. Type I Diabetes: Phase II Results
7.9.4.2. Type II Diabetes: Phase IIb Results
7.9.4.3. Type II Diabetes: Phase IIa Results
7.9.4.4. Type I Diabetes / Type II Diabetes with Renal Impairment
7.9.4.5. As a Combination Therapy
7.9.5. Recent Collaborations
 
8. Discontinued Molecules and Common Side Effects
8.1. Chapter Overview
8.2. DPP4 Inhibitors
8.2.1. Common Side Effects
8.2.2. Warnings Issued by Regulatory Agencies
8.3. SGLT2 Inhibitors
8.3.1. Common Side Effects
8.3.2. Warnings issued by Regulatory Agencies
8.4. GLP-1 Agonists
8.4.1. Common Side Effects
8.4.2. Warnings Issued by Regulatory Agencies
8.5. DPP4 Inhibitors, GLP-1 Agonists, SGLT2 Inhibitors: Terminated Molecules
8.5.1. Distribution by Type of Drug Class and Phase of Development
8.5.2. Distribution by Year of Termination
 
9. Novel Non-Insulin Therapies for Diabetes
9.1. Chapter Overview
9.2. Novel Non-Insulin Therapies for Diabetes
9.2.1. Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Drug Class
9.2.2. Novel Non-Insulin Therapies for Diabetes: Distribution by Phase of Development
9.2.3. Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Molecule
 
10. Market Forecast
10.1. Chapter Overview
10.2. Forecast Methodology
10.3. Overall Non-Insulin Therapies for Diabetes Market
 
10.4. Overall GLP-1 Agonists Market
10.4.1. Liraglutide (1.2mg and 1.8mg)
10.4.2. Exendin-4 / ITCA 650
10.4.3. Exenatide Extended Release
10.4.4. Dulaglutide
10.4.5. Albiglutide
10.4.6. Lixisenatide
10.4.7. Semaglutide Subcutaneous
10.4.8. Liraglutide / Insulin Degludec
10.4.9. Semaglutide Oral / OG217SC / NN9924
10.4.10. Exenatide
10.4.11. Other GLP-1 Agonists
 
10.5. Overall DPP4 Inhibitors Market
10.5.1. Sitagliptin
10.5.2. Vildagliptin
10.5.3. Saxagliptin
10.5.4. Linagliptin
10.5.5. Alogliptin
10.5.6. Gosogliptin
10.5.7. Other DPP4 Inhibitors
10.6. Overall SGLT2 Inhibitors Market
10.6.1. Sotagliflozin
10.6.2. Empagliflozin
10.6.3. Canagliflozin
10.6.4. Dapagliflozin
10.6.5. Tofogliflozin
10.6.6. Ertugliflozin
10.6.7. Bexagliflozin
10.6.8. Other SGLT2 Inhibitors
 
11. Publication Analysis
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. GLP-1 Agonists: List of Publications
11.3.1. Publications on GLP-1 Agonists: Distribution by Focus Drug
11.3.2. Publications on GLP-1 Agonists: Distribution by Key Parameters
 
11.4. DPP4 Inhibitors: List of Publications
11.4.1. Publications on DPP4 Inhibitors: Distribution by Focus Drug
11.4.2. Publications on DPP4 Inhibitors: Distribution by Key Parameters
 
11.5. SGLT2 Inhibitors: List of Publications
11.5.1. Publications on SGLT2 Inhibitors: Distribution by Focus Drug
11.5.2. Publications on SGLT2 Inhibitors: Distribution by Key Parameters
 
12. KOL Analysis
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. GLP-1 Agonists: Key Opinion Leaders
12.3.1. GLP-1 Agonists: Prominent Researchers
12.3.2. GLP-1 Agonists: Leading Key Opinion Leaders
12.4. DPP4 Inhibitors: Key Opinion Leaders
12.4.1. DPP4 Inhibitors: Prominent Researchers
12.4.2. DPP4 Inhibitors: Leading Key Opinion Leaders
12.5. SGLT2 Inhibitors: Key Opinion Leaders
12.5.1. SGLT2 Inhibitors: Prominent Researchers
12.5.2. SGLT2 Inhibitors: Leading Key Opinion Leaders
 
13. Interview Transcripts
 
14. Conclusion
14.1. The Lucrative Anti-Diabetic Drugs Market Presents Immense Opportunity to Novel Non-Insulin Therapies
14.2. GLP-1 Inhibitors and DPP4 Inhibitors Currently Dominate; SGLT2 Inhibitors Have Shown Significant Promise
14.3. Companies Targeting Certain Regional Markets are Amongst the Primary Drivers
14.4. Technological Advances and Innovative Drug Development Approaches are Key to Future Success
14.5. Development of Combination Therapies and Several Novel Drug Classes Are Expected to Promote Future Growth
14.6. Multiple Side Effects Associated with the Use of Certain Drug Classes Remain a Concern
14.7. While the Respective Shares of GLP-1 Agonists and SGLT2 Inhibitors are Projected to Increase, Sales of DPP4 Inhibitors Are Likely to Dip
 
15. Appendix 1: Tabulated Data
 
16. Appendix 2: List of Companies and Organizations

 

List of Figures

Figure 3.1  Diabetes: Diagnostic Limits
Figure 3.2  Non-Insulin Therapies for Diabetes
Figure 4.1 Non-Insulin Therapies: Distribution by Drug Class
Figure 4.2  GLP-1 Agonists: Distribution by Phase of Development
Figure 4.3  GLP-1 Agonists: Key Players
Figure 4.4  GLP-1 Agonists: Distribution by Route of Administration
Figure 4.5  GLP-1 Agonists: Distribution by Dosage Frequency
Figure 4.6  GLP-1 Agonists: Distribution by Type of Molecule
Figure 4.7  DPP4 Inhibitors: Distribution by Phase of Development
Figure 4.8  DPP4 Inhibitors: Key Players
Figure 4.9  DPP4 Inhibitors: Distribution by Type of Therapy 
Figure 4.10  DPP4 Inhibitors: Distribution by Dosage Frequency
Figure 4.11  SGLT2 Inhibitors: Distribution by Phase of Development
Figure 4.12  SGLT2 Inhibitors: Key Players
Figure 4.13  SGLT2 Inhibitors: Distribution by Type of Therapy
Figure 4.14  SGLT2 Inhibitors: Distribution by Dosage Frequency
Figure 4.15  GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors: Key Players
Figure 5.1  Tanzeum® / Eperzan®: Historical Sales, 2014-Q12016 (GBP Million)
Figure 5.2  Trulicity®: Historical Sales, 2014-2015 (USD Million)
Figure 5.3  Trulicity® Historical Sales: Distribution by Region, 2015 (USD Million)
Figure 5.4  ITCA 650: FREEDOM-1 and FREDDOM-1 HBL Clinical Trials 
Figure 6.1  Alogliptin: History of Development
Figure 6.2  Alogliptin: Historical Sales, FY2011-Q1 FY2016 (JPY Billion)
Figure 6.3  Alogliptin Historical Sales: Distribution by Region, FY2015 (JPY Billion)
Figure 7.1  Canagliflozin: History of Development
Figure 7.2 INVOKANA® / INVOKAMET®: Historical Sales, 2013-Q1 2016 (USD Million)
Figure 7.3  INVOKANA® / INVOKAMET® Historical Sales: Distribution by Region, 2015-Q1 2016 (USD Million)
Figure 7.4  Empagliflozin: History of Development
Figure 7.5  Ipragliflozin: History of Development
Figure 8.1  Terminated Molecules: Distribution by Type of Drug Class
Figure 8.2  Terminated Molecules: Distribution by Type of Drug Class and Phase of Development
Figure 8.3  Terminated Molecules: Distribution by Type of Drug Class and Year of Termination
Figure 9.1  Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Drug Class
Figure 9.2  Novel Non-Insulin Therapies for Diabetes: Distribution by Phase of Development
Figure 9.3  Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Molecule
Figure 10.1  Non-Insulin Therapies for Diabetes Market, 2016-2026 (USD Billion)
Figure 10.2  Non-Insulin Therapies for Diabetes Market, 2016-2026: Future Trends and Details
Figure 10.3  Non-Insulin Therapies for Diabetes Market, 2016, 2021 and 2026: Distribution by Type of Drug Class
Figure 10.4  GLP-1 Agonists Market, 2016-2026 (USD Billion)
Figure 10.5  Liraglutide (1.2mg and 1.8mg) Sales Forecast, 2016-2026 (USD Million)
Figure 10.6  Exendin-4 / ITCA 650 Sales Forecast, 2017-2026 (USD Million)
Figure 10.7  Exenatide Extended Release Sales Forecast, 2016-2026 (USD Million)
Figure 10.8  Dulaglutide Sales Forecast, 2016-2026 (USD Million)
Figure 10.9  Albiglutide Sales Forecast, 2016-2026 (USD Million)
Figure 10.10  Lixisenatide Sales Forecast, 2016-2026 (USD Million)
Figure 10.11  Semaglutide/NN9535 Sales Forecast, 2018-2026 (USD Million)
Figure 10.12  Liraglutide / Insulin Degludec Sales Forecast, 2016-2026 (USD Million)
Figure 10.13  Semaglutide Oral / OGC217SC / NN9924 Sales Forecast, 2020-2026 (USD Million)
Figure 10.14  Exenatide Sales Forecast, 2016-2026 (USD Million)
Figure 10.15  DPP4 Inhibitors Market, 2016-2026 (USD Billion)
Figure 10.16  Sitagliptin Sales Forecast, 2016-2026 (USD Million)
Figure 10.17  Vildagliptin Sales Forecast, 2016-2026 (USD Million)
Figure 10.18  Saxagliptin Sales Forecast, 2016-2026 (USD Million)
Figure 10.19  Linagliptin Sales Forecast, 2016-2026 (USD Million)
Figure 10.20  Alogliptin Sales Forecast, 2016-2026 (USD Million)
Figure 10.21  Gosogliptin Sales Forecast, 2017-2026 (USD Million)
Figure 10.22  SGLT2 Inhibitors Market, 2016-2026 (USD Billion)
Figure 10.23  Sotagliflozin Sales Forecast, 2018-2026 (USD Million)
Figure 10.24  Empagliflozin Sales Forecast, 2016-2026 (USD Million)
Figure 10.25  Canagliflozin Sales Forecast, 2016-2026 (USD Million)
Figure 10.26  Dapagliflozin Sales Forecast, 2016-2026 (USD Million)
Figure 10.27  Tofogliflozin Sales Forecast, 2016-2026 (USD Million)
Figure 10.28  Ertugliflozin Sales Forecast, 2018-2026 (USD Million)
Figure 10.29  Bexagliflozin Sales Forecast, 2018-2026 (USD Million)
Figure 11.1  Publications on GLP-1 Agonists: Distribution by Focus Drug
Figure 11.2  Publications on GLP-1 Agonists: Distribution by Study Focus, Publication Month and other Parameters
Figure 11.3  Publications on DPP4 Inhibitors: Distribution by Focus Drug
Figure 11.4  Publications on DPP4 Inhibitors: Distribution by Study Focus, Publication Month and other Parameters
Figure 11.5  Publications on SGLT2 Inhibitors: Distribution by Focus Drug
Figure 11.6  Publications on SGLT2 Inhibitors: Distribution by Study Focus, Publication Month and other Parameters
Figure 12.1  GLP-1 Agonists: Mapping Prominent Researchers
Figure 12.2  GLP-1 Agonists: Leading Key Opinion Leaders
Figure 12.3  DPP4 Inhibitors: Mapping Prominent Researchers
Figure 12.4  DPP4 inhibitors: Leading Key Opinion Leaders
Figure 12.5  SGLT2 Inhibitors: Mapping Prominent Researchers
Figure 12.6  SGLT2 Inhibitors: Leading Key Opinion Leaders
Figure 14.1  Overall Non-Insulin Therapies Market Forecast: Distribution by Drug Class, 2016-2026 (USD Billion)

List of Tables

Table 4.1  Anti-Diabetic Drug Classes: History of Development
Table 4.2  GLP-1 Agonists: Approved Drugs
Table 4.3  GLP-1 Agonists: Pipeline Drugs
Table 4.4  DPP4 Inhibitors: Approved Drugs
Table 4.5  DPP4 Inhibitors: Pipeline Drugs
Table 4.6  SGLT2 Inhibitors: Approved Drugs
Table 4.7  SGLT2 Inhibitors: Pipeline Drugs
Table 5.1  Albiglutide: Product Overview
Table 5.2  Albiglutide: Active / Planned Clinical Trials
Table 5.3  Albiglutide Harmony 2 Clinical Trial: Adverse Events
Table 5.4  Albiglutide Harmony 3 Clinical Trial: Adverse Events
Table 5.5  Albiglutide Harmony 4 Clinical Trial: Adverse Events
Table 5.6  Albiglutide Harmony 5 Clinical Trial: Adverse Events
Table 5.7  Albiglutide Harmony 6 Clinical Trial: Results
Table 5.8  Albiglutide Harmony 6 Clinical Trial: Adverse Events
Table 5.9  Albiglutide Harmony 7 Clinical Trial: Results
Table 5.10  Albiglutide Harmony 7 Clinical Trial: Adverse Events
Table 5.11  Dulaglutide: Product Overview
Table 5.12  Trulicity®: Active / Planned Clinical Trials
Table 5.13  Trulicity®: AWARD Clinical Program Results
Table 5.14  Trulicity®: AWARD-1 Clinical Trial Results
Table 5.15  Trulicity®: AWARD-2 Clinical Trial Results
Table 5.16  Trulicity®: AWARD-3 Clinical Trial Results
Table 5.17  Trulicity®: AWARD-4 Clinical Trial Results
Table 5.18  Trulicity®: AWARD-5 Clinical Trial Results
Table 5.19  Trulicity®: AWARD-6 Clinical Trial Results
Table 5.20  Trulicity®: AWARD-9 Clinical Trial Results
Table 5.21  Trulicity® versus Lantus®: Phase III Clinical Trial Results
Table 5.22  Trulicity® versus Lantus®: Phase III Clinical Trial Adverse Events
Table 5.23  Trulicity® versus Victoza®:  Phase III Clinical Trial Results
Table 5.24  Trulicity® versus Victoza®: Phase III Clinical Trial Adverse Events
Table 5.25  ITCA 650: FREEDOM Clinical Trial Development Program
Table 5.26  ITCA 650: Active / Planned Clinical Trials
Table 5.27  ITCA 650: FREEDOM-2 Clinical Trial Results
Table 5.28  PEX 168: Active / Planned Clinical Trials
Table 5.29  PEX 168: Clinical Trial Results
Table 5.30  Semaglutide: Active / Planned Clinical Trials
Table 5.31  Semaglutide: SUSTAIN Clinical Program Key Characteristics
Table 5.32  Semaglutide: SUSTAIN 1 Clinical Trial Results
Table 5.33  Semaglutide: SUSTAIN 1 Clinical Trial Adverse Events
Table 5.34  Semaglutide: SUSTAIN 3 Clinical Trial Results
Table 5.35  Semaglutide: SUSTAIN 2 Clinical Trial Results
Table 5.36  Semaglutide: SUSTAIN 5 Clinical Trial Results
Table 5.37  Semaglutide: SUSTAIN 4 Clinical Trial Results
Table 5.38  Semaglutide: SUSTAIN 4 Clinical Trial Adverse Events
Table 5.39  Uni-E4: Phase III Clinical Trial Results
Table 6.1  Alogliptin: Product Overview
Table 6.2  Alogliptin: Dosage Form, Regimen and Price
Table 6.3  Alogliptin: Active / Planned Clinical Trials
Table 6.4  Alogliptin EXAMINE Program: Dose and % Recipient Population
Table 6.5  Alogliptin ENDURE Trial: Drug and Dosage Combinations
Table 6.6  Trelagliptin: Active / Planned Clinical Trials
Table 6.7  Omarigliptin: Phase III Clinical Trial Adverse Events
Table 6.8  Evogliptin: Active / Planned Clinical Trials
Table 6.9  Evogliptin: Phase II Clinical Trial Results 
Table 6.10  Retagliptin: Active / Planned Clinical Trials
Table 7.1  Canagliflozin: Product Overview
Table 7.2  Canagliflozin: Dosage Form, Regimen and Price
Table 7.3  Canagliflozin: Active / Planned Clinical Trials
Table 7.4  Canagliflozin as Monotherapy in Older Type II Diabetic Patients: Phase III Clinical Trial Results
Table 7.5  INVOKANA®: First Real-World Analysis
Table 7.6  INVOKANA®: Second Real-World Analysis
Table 7.7  INVOKANA®: Third Real-World Analysis
Table 7.8  Luseogliflozin: Active / Planned Trials
Table 7.9  Tofogliflozin: Active / Planned Clinical Trials
Table 7.10  Empagliflozin: Product Overview
Table 7.11  Empagliflozin: Dosage Form, Regime and Price
Table 7.12  Empagliflozin: Active / Planned Clinical Trials
Table 7.13  Empagliflozin: Retrospective Data (After 12 weeks)
Table 7.14  Empagliflozin: Retrospective Data (After 24 weeks)
Table 7.15  Glyxambi®: Phase III Clinical Trial Results
Table 7.16 Glyxambi®: Phase III Clinical Trial Adverse Events
Table 7.17  Ipragliflozin:  Active / Planned Clinical Trials
Table 7.18  Ipragliflozin as Combination Therapy: Phase III Clinical Trial Results
Table 7.19  Bexagliflozin: Phase II Clinical Trial Results
Table 7.20  Ertugliflozin: Active/Planned Clinical Trials
Table 7.21  Ertugliflozin: Phase III Clinical Trial Results (VERTIS Mono)
Table 7.22  Ertugliflozin: Phase III Clinical Trial Adverse Events (VERTIS Mono)
Table 7.23  Ertugliflozin: Phase III Clinical Trial Results (VERTIS Factorial)
Table 7.24  Ertugliflozin: Phase III Clinical Trial Adverse Events (VERTIS Factorial)
Table 7.25  Sotagliflozin: Active/Planned Clinical Trials
Table 7.26  Sotagliflozin: Phase IIb Study Results, Reduction in HbA1c levels
Table 7.27  Sotagliflozin: Phase IIb Study Results, Reduction in Blood Pressure
Table 7.28  Sotagliflozin: Phase IIa Study Results
Table 8.1  DPP4 Inhibitors: Regulatory Agencies Warnings
Table 8.2  SGLT2 Inhibitors: Regulatory Agencies Warnings
Table 8.3  DPP4 inhibitors/SGLT2 inhibitors/GLP-1 Agonists: Terminated Molecules
Table 9.1  List of Novel Non-Insulin Therapies for Diabetes
Table 11.1  GLP-1 Agonists: List of Publications
Table 11.2  DPP4 Inhibitors: List of Publications
Table 11.3  SGLT2 Inhibitors: List of Publications
Table 12.1  GLP-1 Agonists: List of Key Opinion Leaders
Table 12.2  DPP4 Inhibitors: List of Key Opinion Leaders
Table 12.3  SGLT2 inhibitors: List of Key Opinion Leaders 
Table 15.1  Non-Insulin Therapies: Distribution by Drug Class
Table 15.2  GLP-1 Agonists: Distribution by Phase of Development
Table 15.3  GLP-1 Agonists: Key Players
Table 15.4  GLP-1 Agonists: Distribution by Route of Administration
Table 15.5  GLP-1 Agonists: Distribution by Dosage Frequency
Table 15.6  GLP-1 Agonists: Distribution by Type of Molecule
Table 15.7  DPP4 Inhibitors: Distribution by Phase of Development
Table 15.8  DPP4 Inhibitors: Key Players
Table 15.9  DPP4 Inhibitors: Distribution by Type of Therapy
Table 15.10  DPP4 Inhibitors: Distribution by Dosage Frequency
Table 15.11  SGLT2 Inhibitors: Distribution by Phase of Development
Table 15.12  SGLT2 Inhibitors: Key Players
Table 15.13  SGLT2 Inhibitors: Distribution by Type of Therapy
Table 15.14  SGLT2 Inhibitors: Distribution by Dosage Frequency
Table 15.15  GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors: Key Players
Table 15.16  Tanzeum® / Eperzan®: Historical Sales, 2014-Q12016 (GBP Million)
Table 15.17  Trulicity®: Historical Sales, 2014-2015 (USD Million)
Table 15.18  Trulicity® Historical Sales: Distribution by Region, 2015 (USD Million)
Table 15.19  Alogliptin: Historical Sales, FY2011-Q1 FY2016 (JPY Billion)
Table 15.20  Alogliptin Historical Sales: Distribution by Region, FY2015 (JPY Billion)
Table 15.21  INVOKANA® / INVOKAMET®: Historical Sales, 2013-Q1 2016 (USD Million)
Table 15.22  INVOKANA® / INVOKAMET® Historical Sales: Distribution by Region, 2015-Q1 2016 (USD Million)
Table 15.23  Terminated Molecules: Distribution by Type of Drug Class
Table 15.24  Terminated Molecules: Distribution by Type of Drug Class and Phase of Development
Table 15.25  Terminated Molecules: Distribution by Type of Drug Class and Year of Termination
Table 15.26  Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Drug Class
Table 15.27  Novel Non-Insulin Therapies for Diabetes: Distribution by Phase of Development
Table 15.28  Novel Non-Insulin Therapies for Diabetes: Distribution by Type of Molecule
Table 15.29  Non-Insulin Therapies for Diabetes Market, 2016-2026 (USD Billion)
Table 15.30  Non-Insulin Therapies for Diabetes Market, 2016, 2021 and 2026: Distribution by Type of Drug Class
Table 15.31  GLP-1 Agonists Market, 2016-2026 (USD Billion)
Table 15.32  Liraglutide (1.2mg and 1.8mg) Sales Forecast, 2016-2026 (USD Million)
Table 15.33  Exendin-4 / ITCA 650 Sales Forecast, 2017-2026 (USD Million)
Table 15.34  Exenatide Extended Release Sales Forecast, 2016-2026 (USD Million)
Table 15.35  Dulaglutide Sales Forecast, 2016-2026 (USD Million)
Table 15.36  Albiglutide Sales Forecast, 2016-2026 (USD Million)
Table 15.37  Lixisenatide Sales Forecast, 2016-2026 (USD Million)
Table 15.38  Semaglutide/NN9535 Sales Forecast, 2018-2026 (USD Million)
Table 15.39  Liraglutide / Insulin Degludec Sales Forecast, 2016-2026 (USD Million)
Table 15.40  Semaglutide Oral / OGC217SC / NN9924 Sales Forecast, 2020-2026 (USD Million)
Table 15.41  Exenatide Sales Forecast, 2016-2026 (USD Million)
Table 15.42  DPP4 Inhibitors Market, 2016-2026 (USD Billion)
Table 15.43  Sitagliptin Sales Forecast, 2016-2026 (USD Million)
Table 15.44  Vildagliptin Sales Forecast, 2016-2026 (USD Million)
Table 15.45  Saxagliptin Sales Forecast, 2016-2026 (USD Million)
Table 15.46  Linagliptin Sales Forecast, 2016-2026 (USD Million)
Table 15.47  Alogliptin Sales Forecast, 2016-2026 (USD Million)
Table 15.48  Gosogliptin Sales Forecast, 2017-2026 (USD Million)
Table 15.49  SGLT2 Inhibitors Market, 2016-2026 (USD Billion)
Table 15.50  Sotagliflozin Sales Forecast, 2018-2026 (USD Million)
Table 15.51  Empagliflozin Sales Forecast, 2016-2026 (USD Million)
Table 15.52  Canagliflozin Sales Forecast, 2016-2026 (USD Million)
Table 15.53  Dapagliflozin Sales Forecast, 2016-2026 (USD Million)
Table 15.54  Tofogliflozin Sales Forecast, 2016-2026 (USD Million)
Table 15.55  Ertugliflozin Sales Forecast, 2018-2026 (USD Million)
Table 15.56  Bexagliflozin Sales Forecast, 2018-2026 (USD Million)
Table 15.57  Publications on GLP-1 Agonists: Distribution by Focus Drug
Table 15.58  Publications on DPP4 Inhibitors: Distribution by Focus Drug
Table 15.59  Publications on SGLT2 Inhibitors: Distribution by Focus Drug
Table 15.60  Overall Non-Insulin Therapies Market Forecast: Distribution by Drug Class, 2016-2026 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 3sBio
  2. Aalborg Hospital
  3. Aarhus University Hospital
  4. Abbott Laboratories
  5. ActivX Biosciences
  6. Addex Therapeutics
  7. Aegis Therapeutics
  8. AGDUC
  9. AIDS Clinical Trials Group
  10. Ajinomoto
  11. Alantos Pharmaceuticals
  12. Albert Einstein College of Medicine
  13. Alize Pharma
  14. Alkem Labs
  15. Alkermers
  16. Allegheny Health Network
  17. Allergan
  18. Almirall
  19. Alteogen
  20. ALZA Pharmaceuticals
  21. American Association of Clinical Endocrinologists
  22. American Diabetes Association
  23. American Heart Association
  24. Amgen
  25. Amunix
  26. Amylin Pharmaceuticals
  27. AntriaBio
  28. ArisGen
  29. Arisaph Pharmaceuticals
  30. Asan Medical Center
  31. Ascendis Pharma
  32. Assistance Publique Hopitaux De Marseille
  33. Astellas Pharma
  34. AstraZeneca
  35. Atlanta VA Medical Center
  36. Audie L.  Murphy VA Hospital
  37. Aventis
  38. Avexxin
  39. Banyu Pharmaceutical
  40. Bayer Pharmaceuticals
  41. Baylor College of Medicine
  42. Baylor Research Institute
  43. Beijing Tongren Hospital
  44. Besançon Regional University Hospital
  45. Beth Israel Deaconess Medical Center
  46. BHV Pharma
  47. Bio-Ker
  48. Biolaxy
  49. BioLineRx
  50. Birmingham City Hospital
  51. Bispebjerg Hospital
  52. Boehringer Ingelheim
  53. Boramae Medical Center
  54. Boston Medical Center
  55. Brigham and Women's Hospital
  56. Bristol-Myers Squibb
  57. C4XD
  58. Cadila Healthcare Limited
  59. Cambridge Healthtech Institute
  60. Carl T. Hayden Medical Research Foundation
  61. Cedars-Sinai Medical Center
  62. Celerion
  63. Celgene
  64. CellMed
  65. Center for Human Drug Research
  66. Centers for Disease Control and Prevention
  67. Centre for Prognosis Studies in the Rheumatic Diseases
  68. Centre Hospitalier De Valenciennes
  69. Centre Hospitalier Sud Francilien
  70. Centre Hospitalier Universitaire Amiens
  71. Centro de Diabetes Curitiba
  72. CERITD
  73. Chang Gung Memorial Hospital
  74. Charles Drew University of Medicine and Science
  75. Charles University
  76. ChemRar High Tech Center
  77. Children's Healthcare of Atlanta
  78. Children's Heart Surgery Fund
  79. Children's Hospital of Philadelphia
  80. China-Japan Friendship Hospital
  81. Chinese PLA General Hospital
  82. Chinese University of Hong Kong
  83. Chonbuk National University Hospital
  84. CHU de Québec
  85. CHU Dijon
  86. Chugai Pharmaceutical
  87. Cincinnati Children's Hospital Medical Center
  88. Clinical Pharmacology Unit, Belgium
  89. Clinique Saint-Anne Strasbourg
  90. Clinique Sainte-Anne - AURAL Strasbourg
  91. Colorado State University
  92. Committee for Medicinal Products for Human Use
  93. ConjuChem Biotechnologies
  94. Connexios Life Sciences
  95. Copenhagen University Hospital
  96. Cornell CRS    
  97. CoSynance Therapeutics
  98. CSL Behring
  99. CSPC Pharma
  100. CureDM
  101. CymaBay Therapeutics
  102. Daewoong Pharmaceutical
  103. Daiichi Sankyo
  104. Dainippon Sumitomo Pharma
  105. Dance Biopharm
  106. Diabetes Foundation
  107. Diabeteszentrum Bad Lauterberg
  108. Diabetes-Zentrum Quakenbruck
  109. Diabetology
  110. Diamyd Medical
  111. Diartis Pharmaceuticals
  112. Dokkyo Medical University
  113. Dong-A Pharmaceutical
  114. Dongguk University College of Medicine
  115. Double-Crane Pharmaceutical
  116. Dr. A. Ramachandran's Diabetes Hospital
  117. Duke University
  118. Eisai
  119. Eli Lilly
  120. Emisphere Technologies
  121. Emory University
  122. Eurofarma
  123. European Association for the Study of Diabetes
  124. Farallon Capital Management
  125. Federal University of Rio Grande do Sul
  126. Ferring Pharmaceutical
  127. Flamel Technologies
  128. Foresee Pharmaceuticals
  129. Foresite Capital
  130. Forest Laboratories
  131. Franklin Templeton
  132. Fred Alger Management
  133. Friedrich-Alexander-Universität Erlangen-Nürnberg
  134. Fudan University
  135. Fundação Faculdade Regional de Medicina de São José do Rio Preto
  136. Fuwai Hospital
  137. GalaxoSmithKline
  138. Gastroenterology Department Erasme Hospital
  139. General Hospital of People's Liberation Army Chengdu Military Region
  140. Genexine
  141. Gentofte Hospital
  142. Genzyme
  143. Geropharm
  144. Glasgow Royal Infirmary
  145. Glenmark Pharmaceuticals
  146. Glide Technologies
  147. Grady Memorial Hospital
  148. Greensboro CRS
  149. Guy's and St Thomas' Hospitals
  150. GWT-TUD
  151. Hadassah Ein Kerem
  152. Hadassah Medical Organization
  153. Handok Pharmaceuticals
  154. Hanmi Pharmaceuticals
  155. Harvard University
  156. Hatter Cardiovascular Institute
  157. Haywood Regional Medical Center
  158. Heart Institute (InCor)
  159. Hebrew University
  160. Herlev Hospital
  161. Hopital cardiologique Louis Pradel
  162. Hospices Civils de Colmar
  163. Hospital Clinic of Barcelona
  164. Hospital Clínico de Madrid
  165. Hospital General Carlos Haya
  166. Hospital General de Segovia
  167. Hospital of the Holy Cross and Saint Paul
  168. Hospital Universitario Insular
  169. Houston AIDS Research Team CRS
  170. Hua Medicine
  171. Huashan Hospital
  172. Hvidovre University Hospital
  173. Hyundai Pharmaceutical
  174. Ildong Pharmaceutical
  175. Ilsan Hospital
  176. ImmuPharma
  177. Imperial College London
  178. Indiana University
  179. Institut de Recherches Cliniques de Montreal
  180. Institut für Pharmakologie und Präventive Medizin
  181. Institut National de la Santé Et de la Recherche Médicale
  182. Institute for Medical Research
  183. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
  184. Intarcia Therapeutics
  185. Intercept Pharmaceuticals
  186. International Diabetes Federation
  187. International Society for Pharmacoeconomics and Outcomes Research
  188. Ionis Pharmaceuticals
  189. Ipsen
  190. IRCCS Policlinico San Matteo Foundation
  191. Islet Lifesciences
  192. Janssen
  193. Jean Verdier Hospital
  194. JHL Biotech
  195. Jiangsu Hansoh Pharmaceutical
  196. Jiangsu Hengrui Medicine
  197. Jiangsu Provincial People's Hospital
  198. Johnson and Johnson
  199. Joslin Diabetes Center
  200. Jothydev's Diabetes and Research Center
  201. Juntendo University School of Medicine
  202. Juvenile Diabetes Research Foundation
  203. Kalypsys
  204. Kanazawa University
  205. Kangbuk Samsung Hospital
  206. Kansai Electric Power Hospital
  207. Karolinska Institutet
  208. Katobuki Pharmaceutical
  209. Kevan Herold
  210. Khoo Teck Puat Hospital
  211. Kinderkrankenhaus auf der Butl
  212. KineMed
  213. King's College London
  214. Kirchhain
  215. Kissei Pharmaceutical
  216. Koege University Hospital
  217. Korea University
  218. Kotobuki Pharmaceutical
  219. Kowa Pharmaceutical
  220. Kurume University
  221. Kyorin Pharmaceutical
  222. Kyoto University
  223. Kyowa Hakko Kirin Company
  224. Kyunghee University Medical Center
  225. Laval University
  226. Leicester General Hospital
  227. Leiden University Medical Center
  228. Lexicon
  229. LG Life Sciences
  230. Ligand Pharmaceuticals
  231. Lund University
  232. Lunenfeld Tanenbaum Research Institute
  233. Lupin
  234. Luye Pharma Group
  235. Mackay Memorial Hospital
  236. MacroGenics
  237. Mannkind Corporation
  238. Marcadia Biotech
  239. Massachusetts General Hospital
  240. Mayo Clinic
  241. Medanta Medicity
  242. Medical College of Wisconsin
  243. Medical University Innsbruck
  244. Medical University of Graz
  245. Medical University of Silesia
  246. Medical University of Vienna
  247. Medico Moving Center Institute, Formosa
  248. MedImmune
  249. Menarini Group
  250. Merck
  251. Merrion Pharmaceuticals
  252. Metabasis Therapeutics
  253. Metabolic Center of Louisiana Resarch Foundation
  254. Mid America Heart Institute Saint Luke's Health System
  255. MidaSol Therapeutics
  256. Mitsubishi Tanabe Pharma
  257. Mitusui Memorial Hospital
  258. MonoSol Rx
  259. Mount Sinai Hospital, Canada
  260. Mountain Diabetes and Endocrine Center
  261. MultiMedica
  262. Nanjing Drum Tower Hospital
  263. National Cerebral and Cardiovascular Center
  264. National Health Research Institutes
  265. National Institues of Health
  266. National Institute for Health and Care Excellence
  267. National Institute of Diabetes and Digestive and Kidney Diseases
  268. National Institute on Aging
  269. National Taiwan University Hospital
  270. Nemours Children's Clinic
  271. New Enterprise Associates
  272. New Leaf Venture Partners
  273. New York Obesity Nutrition Research Center
  274. NIHR Exeter Clinical Research Facility
  275. Nobel İlaç'
  276. NOD Pharmaceuticals
  277. Norwegian University of Science and Technology
  278. Novartis
  279. Novo Nordisk
  280. NU Hospital Organization
  281. Numab
  282. OctoPlus
  283. Ohio State University
  284. Ono Pharmaceutical
  285. OPKO Biologics
  286. Optum
  287. Oramed Pharmaceuticals
  288. Örebro University
  289. Oregon Health and Science University
  290. Osaka University Graduate
  291. Oslo University Hospital Ullevaal
  292. Otsuka Pharmaceutical
  293. Panacea Biotec
  294. PAREXEL International
  295. Park Nicollet International Diabetes Center
  296. PegBio
  297. Peking Union Medical College Hospital
  298. Pennington Biomedical Research Center
  299. People's Hospital, Peking Universty
  300. Peptron
  301. Pfizer
  302. Pharmaceutical Product Development
  303. PharmaIN
  304. Pharmsynthez
  305. PhaseBio Pharmaceuticals
  306. Phenomix
  307. Phoenix VA Healthcare System
  308. Phoundry Pharmaceuticals
  309. Pitié-Salpêtrière Hospital
  310. Palatin Technologies
  311. Pontificia Universidad Catolica de Chile
  312. Population Health Research Institute
  313. Post Graduate Institute of Medical Education and Research
  314. Poxel
  315. Prism Research
  316. Probiodrug
  317. Profil Institut für Stoffwechselforschung
  318. Profil Institute for Metabolic Research
  319. Prosidion
  320. Pusan National University Hospital
  321. Pusat Perubatan Universiti Kebangsaan
  322. Qianfoshan Hospital
  323. Quilvest
  324. Quintiles
  325. Quotient Bioresearch Clinical Services
  326. RA Capital
  327. Radboud University
  328. Rani Therapeutics
  329. Receptos
  330. Rigshospitalet
  331. Rikshospitalet Medical Center
  332. Roche
  333. Royal Adelaide Hospital
  334. Royal Bournemouth Hospital
  335. Royal Devon & Exeter NHS Trust
  336. Royal Surrey County Hospital
  337. Royalty Pharma
  338. Ruhr-University Bochum
  339. Saint Luke's Mid America Heart Institute
  340. Samsung Medical Center
  341. Sana Klinikum Offenbach
  342. Sanofi
  343. Sanwa Kagaku Kenkyusho
  344. Sao Paulo General Hospital
  345. SatRx
  346. Scientisic Research Institute of Cardiology and Internal Diseases
  347. ScinoPharm
  348. Seattle Children's Hospital
  349. Second University of Naples
  350. Second Xiangya Hospital of Central South University
  351. Seoul National University Bundang Hospital
  352. Seoul St. Mary's Hospital
  353. Serometrix
  354. Services Hospital
  355. Servier
  356. Severance Hospital
  357. Shandong Provincial Hospital
  358. Shanghai Jiao Tong University School of Medicine
  359. Shanghai Mental Health Center
  360. Shanghai Sixth People's Hospital
  361. Sheba Medical Center
  362. Sirona Biochem
  363. Slotervaart Hospital
  364. Spitfire Pharma
  365. St Michael's Hospital
  366. St. Josef Hospital
  367. St. Joseph's Health Care, London
  368. Stanford University
  369. Stendhal
  370. Steno Diabetes Center
  371. Sumitomo Dainippon Pharma
  372. Sun Pharma Advanced Research
  373. Sun Yat-Sen University
  374. Sydney Diabetes Centre
  375. Taichung Veterans General Hospital
  376. Taipei Medical University WanFang Hospital
  377. Taisho Pharmaceutical
  378. Takeda
  379. Tampere University Hospital
  380. Tarix Pharmaceuticals
  381. Teijin Pharma
  382. Teva Active Pharmaceutical Ingredients
  383. The Baupost Group
  384. The Catholic University of Korea
  385. The First Affiliated Hospital of Xi’an Jiaotong University
  386. The First Affiliated Hospital of Xiamen University
  387. The First Affiliated Hospital of Zhejiang University
  388. The George Institute for Global Health
  389. The George Washington University Medical Faculty Associates
  390. The National Center for Scientific Research
  391. The Third Xiangya Hospital of Center South University
  392. Theracos
  393. Therapix Biosciences
  394. Theratechnologies
  395. Third Military Medical University, China
  396. Thomas Jefferson University
  397. TIMI Study Group
  398. Tobira Therapeutics
  399. Tolerx
  400. Toronto Western Hospital 
  401. Transition Therapeutics
  402. TransTech Pharma
  403. Tulane University
  404. Turku PET Centre
  405. Turku University Hospital
  406. UCL Institute of Neurology
  407. UKMMC
  408. UMass Medical School
  409. Uni-Bio Science Group
  410. Universität zu Lübeck
  411. Université de Lorraine
  412. Université de Montréal
  413. University at Buffalo
  414. University College Dublin
  415. University Health Network
  416. University Hospital Center of Toulouse
  417. University Hospital of Basel
  418. University Hospital of Caen
  419. University Hospital of Palermo
  420. University Medical Center Groningen
  421. University Medical Center Hamburg-Eppendorf
  422. University Medical Center Ljubljana,Slovenia
  423. University Nijmegen Medical Center
  424. University of Aarhus
  425. University of Adelaide
  426. University of Alabama at Birmingham
  427. University of Alberta
  428. University of Amsterdam
  429. University of Birmingham
  430. University of Bordeaux
  431. University of British Columbia
  432. University of California
  433. University of California, Davis
  434. University of California, Los Angeles
  435. University of Chicago
  436. University of Cincinnati
  437. University of Colorado
  438. University of Copenhagen
  439. University of Dundee
  440. University of Exeter
  441. University of Geneva
  442. University of Guadalajara
  443. University of Illinois at Chicago
  444. University of Leicester
  445. University of Manchester
  446. University of Maryland
  447. University of Miami
  448. University of Michigan
  449. University of Minnesota
  450. University of Munich
  451. University of Nebraska-Lincoln
  452. University of Nevada School of Medicine
  453. University of North Carolina, Chapel Hill
  454. University of Nottingham
  455. University of Oulu
  456. University of Padova Medical School
  457. University of Palermo
  458. University of Pennsylvania
  459. University of Pittsburgh
  460. University of São Paulo General Hospital
  461. University of Southern California
  462. University of Surrey
  463. University of Tartu
  464. University of Texas
  465. University of Texas Health Science Center
  466. University of Texas Medical Branch
  467. University of the Ryukyus
  468. University of Tokyo
  469. University of Toronto
  470. University of Washington
  471. University of Western Ontario
  472. Uppsala University
  473. UT Southwestern Medical Center
  474. VA Puget Sound Health Care System
  475. Vall d'Hebron Research Institute
  476. Vanderbilt University School of Medicine
  477. Velocity Pharmaceutical Development
  478. Venrock
  479. Viking Therapeutics
  480. Vitae Pharmaceuticals
  481. VIVUS
  482. vTv Therapeutics
  483. VU University Medical Center
  484. Wake Forest University / Wake Forest University Health Sciences
  485. Walter Reed Army Medical Center- Diabetes Institute
  486. Wan Fang Hospital
  487. Wanbang Biopharmaceuticals (subsidiary of Shanghai Pharmaceutical Group)
  488. Washington University CRS
  489. Washington University School of Medicine
  490. Woman's Hospital
  491. World Health Organization
  492. Wuhan General Hospital of Guangzhou Command
  493. Xenetic Biosciences
  494. Yale University
  495. Yeshiva University
  496. Yokohama City University School of Medicine
  497. Yuhan
  498. Zealand Pharma
  499. Zosano Pharma
  500. Zydus Cadila
  501. ZymoGenetics
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 2,349

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com